Clinical Trial Update: Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating nivolumab in combination with chemo-immunotherapy for newly diagnosed primary mediastinal large B-cell lymphoma is active-not-recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mediastinal Large B-cell Lymphoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Primary Mediastinal Large B-Cell Lymphoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING